Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05278637 · ClinicalTrials.gov registry record · Early Phase 1
GM03 - Platelet RNA Signatures of Aspirin
A Early Phase 1 study of RNA and Aspirin, sponsored by Duke University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 135
- Enrollment target
- 1
- Study location
NCT05278637 is a Early Phase 1 study of RNA and Aspirin that has completed, run by Duke University. The registered enrollment target is 135 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05278637, a Early Phase 1 study of RNA and Aspirin, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 135 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will involve healthy volunteers and patients with Type 2 diabetes. Eligible healthy volunteers will be invited to enroll into one of two protocols (A or B) and eligible patients with diabetes will be enrolled into protocol A.
Conditions Studied
Interventions
- DRUG Aspirin
- DRUG Ticagrelor
Study Locations (1)
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2013-11-01 |
| Est. Completion | 2016-12-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05278637
The ClinicalTrials.gov registry entry for NCT05278637 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with RNA appearing as the primary indexed condition, and to 2 interventions - of which Aspirin is the first listed.
NCT05278637 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05278637 about?
NCT05278637 is a clinical study titled "GM03 - Platelet RNA Signatures of Aspirin". This study will involve healthy volunteers and patients with Type 2 diabetes. Eligible healthy volunteers will be invited to enroll into one of two protocols (A or B) and eligible patients with diabetes will be enrolled into protocol A.
What is the current status of trial NCT05278637?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 135 participants. The study started on 2013-11-01. Estimated completion is 2016-12-05.
What conditions does trial NCT05278637 study?
This clinical trial studies the following conditions: RNA, Aspirin, Platelet Aggregation Inhibitors, Ticagrelor.
What interventions are being tested in trial NCT05278637?
The interventions under investigation include: Aspirin (DRUG), Ticagrelor (DRUG).
Who is sponsoring clinical trial NCT05278637?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05278637 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for RNA
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.